文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

脑室内注射靶向B7-H3的CAR T细胞治疗弥漫性内生性脑桥胶质瘤:一项1期试验

Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial.
PubMed 文献 · Nat Med · 2025-01-07

这项单中心、剂量递增1期试验纳入23例弥漫性内生性脑桥胶质瘤(DIPG)患儿,21例接受重复脑室内(ICV)B7-H3 CAR T细胞治疗,未行淋巴细胞清除。主要目标可行性与耐受性均达到,确定最高计划剂量方案DR4(每剂最高10×10^7细胞)为最大耐受剂量方案;全部治疗患者中位生存期自首次输注起为10.7个月,自诊断起为19.8个月。

要点

  • 重复ICV B7-H3 CAR T细胞治疗DIPG可行且可耐受,包括多年重复给药。
  • 确定DR4(每剂最高10×10^7细胞)为最大耐受剂量方案。
  • 全部治疗患者自首次输注中位生存10.7个月,自诊断中位生存19.8个月。

核心结论

  • 这项已完成的首人体试验表明,对儿童及年轻成人DIPG患者重复ICV给予B7-H3 CAR T细胞可耐受,包括多年重复给药,并可能有临床疗效,值得在多中心2期试验中进一步研究。

研究设计与样本

  • 单中心、剂量递增1期临床试验BrainChild-03的C组,仅纳入DIPG患者。
  • 共23例DIPG患者入组,21例接受重复ICV B7-H3 CAR T细胞治疗,采用患者内剂量递增方案,未行淋巴细胞清除。
  • 方案治疗期间不允许同时进行肿瘤导向治疗(包括再照射)。
  • 共给予253次ICV剂量。

主要发现

  • 主要目标可行性与耐受性均达到。
  • 确定最高计划剂量方案DR4(每剂递增至10×10^7细胞)为最大耐受剂量方案。
  • 常见不良事件包括头痛、疲乏和发热。
  • DR2期间发生1例剂量限制性毒性(瘤内出血)。
  • 全部治疗患者(n=21)自首次CAR T细胞输注起中位生存期为10.7个月,自诊断起中位生存期为19.8个月,3例患者自诊断起分别存活44、45和52个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we conducted BrainChild-03, a single-center, dose-escalation phase 1 clinical trial of repetitive intracerebroventricular (ICV) dosing of B7-H3-targeting chimeric antigen receptor T cells (B7-H3 CAR T cells) for children with recurrent or refractory CNS tumors and DIPG. Here we report results from Arm C, restricted to patients with DIPG. The primary objectives were to assess feasibility and tolerability, which were both met. Secondary objectives included assessments of CAR T cell distribution and survival. A total of 23 patients with DIPG enrolled, and 21 were treated with repeated doses of ICV B7-H3 CAR T cells using intra-patient dose-escalation regimens without previous lymphodepletion. Concurrent tumor-directed therapy, including re-irradiation, was not allowed while on protocol therapy. We delivered a total of 253 ICV doses and established the highest planned dose regimen, DR4, which escalated up to 10 × 107 cells per dose, as the maximally tolerated dose regimen. Common adverse events included headache, fatigue and fever. There was one dose-limiting toxicity (intratumoral hemorrhage) during DR2. For all treated patients (n = 21), the median survival from their initial CAR T cell infusion was 10.7 months and the median survival from diagnosis was 19.8 months with 3 patients still alive at 44, 45 and 52 months from diagnosis. Ultimately, this completed first-in-human trial shows that repetitive ICV dosing of B7-H3 CAR T cells in pediatric and young adult patients with DIPG is tolerable, including multiyear repeated dosing, and may have clinical efficacy that warrants further investigation on a multisite phase 2 trial. ClinicalTrials.gov registration: NCT04185038 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Vitanza NA, Ronsley R, Choe M, et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med. 2025. PMID: 39775044. doi:10.1038/s41591-024-03451-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。